Investor PresentationSpring 2021

The Future of Cancer Immunotherapy

1

BriaCell Therapeutics Corp.Nasdaq: BCTX, BCTXW

TSXV: BCT

Forward-Looking Statements

BriaCell Therapeutics Corp. (“BriaCell”)

Except for historical information, this presentation contains forward-looking statements, whichreflect BriaCell’s current expectations regarding future events. These forward-looking statementsinvolve known and unknown risks and uncertainties that could cause BriaCell’s actual results todiffer materially from those statements. Those risks and uncertainties include, but are not limitedto, our ability to access capital, the successful and timely completion of clinical trials, the receipt ofall regulatory approvals and other risks detailed in our our registration statement on Form F‐1 whichwe filed with the Securities and Exchange Commission on February 21, 2020, as amended from timeto time and available at www.sec.gov. The forward-looking statements in this presentation are alsobased on a number of assumptions which may prove to be incorrect.

Forward-looking statements contained in this presentation represent views only as of the date ofthis presentation and are presented for the purpose of assisting potential investors in understandingBriaCell’s business, and may not be appropriate for other purposes. BriaCell does not undertake toupdate forward-looking statements, whether written or oral, that may be made from time to timeby or on its behalf, except as required under applicable securities legislation.

2

Capitalization Structure

3

Nasdaq: BCTX, BCTXWTSXV: BCT

Share Price (as of 3/18/21): US$3.88

Shares Outstanding: 5,624,313

Market Cap: US$22M

Common Shares issuable upon exercise of pre-funded warrants:

1,030,000

Options (US$36.58 WAEP): 18,052

Warrants (US$6.14 WAEP): 6,442,867

Cash (pro-forma for 2/26/21 $25M financing,

excluding underwriting discounts, commissions, and other offering expenses):

$25M

Website: www.BriaCell.com

Stock Symbols:

BriaCell Corporate Highlights

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSXV: BCT) is a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors

Lead drug candidate Bria-IMT™ is targeting third-line advanced breast cancer (the cause of over 40,000 deaths per year in the U.S.) and its associated U.S. patient population of ~70,000 patients

35 patients dosed to-date show robust response Our Phase I/IIa safety & efficacy show similar or superior results to those of other advanced or approved drugs for breast cancer at similar clinical stages of development

Incyte Corporation (Nasdaq: INCY) Corporate collaboration and supply agreement

Non-exclusive clinical trial collaboration to evaluate the effects of combination therapies

Bria-IMT™ + immune checkpoint inhibitors (Phase I/IIa)

1. Bria-IMT™ + pembrolizumab (KEYTRUDA®); dosed 11 patients transitioned to Incyte combination2. Bria-IMT™ + Incyte’s selected compounds under corporate collaboration

Registration Study initiation expected early-2022 Bria-IMT™ combined with immune checkpoint inhibitor

Bria-OTS™ “Off-The-Shelf Personalized” immunotherapy based on patient’s HLA-type that would address ~140,000 third-line breast cancer patients (99% of all third-line patients)

R&D Agreement with the National Cancer Institute (part of NIH)

CEO Dr. William Williams has been involved in 11 drug approvals

4Advancing towards pivotal early 2022 registration study commencement

William V. Williams, MD, FACP, President & CEO, Director Former VP, Exploratory Development, Incyte Corporation Former VP, Experimental Medicine, GlaxoSmithKline Former Head, Rheumatology Research, University of Pennsylvania Extensive drug development experience

Charles Wiseman, MD, Co-Founder & Director Former Assistant Professor at The University of Texas MD Anderson

Cancer Center Former Director, Immunotherapy Lab, St. Vincent Medical Center Clinical Professor of Medicine (retired), Keck-USC School of Medicine Former Acting Chief of the Division of Oncology/Hematology at the

White Memorial Medical Center

Rebecca A. Taub, MD, Director Current: CMO & EVP, Director, Founder, Madrigal Pharmaceuticals Senior VP, VIA Pharmaceuticals VP of Research, Metabolic Diseases, Hoffmann-La Roche Company Executive Director, Bristol-Myers Squibb Executive Director, Dupont Pharmaceuticals Professor of Genetics and Medicine, University of Pennsylvania

BriaCell’s Expert Drug Development & Financial Team

5

Jamieson Bondarenko, CFA, CMT, Chairman of the Board Previously Principal and Managing Director of the Equity Capital Markets group

of Eight Capital Previously several positions at Dundee Securities Ltd., including Managing

Director, Director, Vice President and Associate

Vaughn Embro-Pantalony, MBA, FCPA, FCMA, CDir, ACC, Director Current: Chair, Board of Directors, Soricimed Biopharma Inc. Board and Audit Committee Member, Microbix Biosystems Inc. VP, Finance & CFO, Teva Novopharm Limited VP, Finance & Administration, Bayer Healthcare Director, Finance and Administration & CFO, Zeneca Pharma Inc.

Martin Schmieg, CPA, Director Current: CEO, ClearIT, LLC CFO: Sirna Therapeutics, Inc., & Isolagen, Inc. CEO, Freedom-2, Inc. (now PharmaCyte, Inc.) Advisor, Caladrius Biosciences, Inc., Beckman Coulter Genomics, Calimmune,

Inc., Cryoport, Inc., Vetbiologics, a division of U.S. Stem Cell, Inc., Sapientia Pharmaceuticals, Inc., & Rokk3r Labs, LLC

CEO Dr. William Williams was involved in 11 drug approvals in his career

6

*NICL = Novel Immunotherapy Cell Lines **PKCδi = Protein kinase C delta inhibitor §Each of these IND filings would require an additional ~$1M above the baseline budget

BriaCell Pipeline

Therapeutic Indication Preclinical Phase I Phase II Phase III Anticipated Milestones

Bria-IMT™ + Incyte Compounds

Advanced Breast Cancer (3rd+ line)

Further safety and efficacy data through 2021

Bria-OTS™ Breast Cancer IND filing 2021

NICL1* Prostate Cancer IND Filing 2022

NICL2*Non-Small Cell Lung Cancer

IND Filing 2022

NICL3* Melanoma IND Filing 2022

Bria-TILsRx™ Prostate Cancer IND Filing 2022§

Bria-TILsRx™ Epithelial and Glandular IND Filing 2022§

PKCδi** RAS Transformed Cancers Candidate Selection 2021

Phase I/II

BriaCell’s Patented Immunotherapy: Bria-IMT™

7

Mechanism of Action: Specific Immune Activation directly stimulates cancer-fighting cells in advanced breast cancer

Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.

We believe that Bria-IMT™:

1. Produces antigens (proteins made by breast cancer cells).

2. Further boosts the immune response through secretion of a protein called GM-CSF.

3. The antigens are ‘presented’ to CD4+ and CD8+ T-cells, cells known for tumor destruction.

4. Also directly stimulates cancer-fighting T-cells, further boosting the response.

Bria-IMT™

Antigens

GM-CSF

CD4+

CD8+Tumor Destruction

PatientsHLA

MatchDisease Control*

Disease Control in Immune

Responders**

N=6 ≥ 2 50% 75%

N=20 ≥ 1 25% 33%

N=7 0 29% 29%

8

*Includes 1 PR and 7 SD**Immune response measured by delayed-type hypersensitivity.

Bria-IMT™ – Phase I/IIa Efficacy in Breast Cancer

HLA-Type Matching and Biological Activity (original patients + Phase I/IIa data)

Patient 01-002 – Two HLA Matches

Patient 01-002 was treated with the Bria-IMT™ regimen and had what we conclude was a robust response, specifically substantial tumor regression in 20 lung metastases that all either disappeared or shrunk to tiny scars.

Pre-Treatment Post-Treatment

HLA Matching Hypothesis: Tumor regression appears to be most pronounced in patients who match Bria-IMT™ at specific HLA-types & develop an immune response

4 patients treated by Dr. Wiseman in 2004-2005 (original patients), including one remarkable responder.

23 patients were dosed in 2017-2018 (Phase I/IIa), all very heavily pre-treated (with chemotherapy).

Safety & Efficacy Data: We believe the data was similar or superior to those of other advanced or approved drugs for breast cancer at similar clinical stages of development.

Mechanism of Action & Proof-of-Concept

Bria-IMT™ in Combination with Immune Checkpoint Inhibitors

9

Why did we combine Bria-IMT™ with immune checkpoint inhibitors?

• BriaCell has observed PD-L1 expression on circulating cancer cells & cancer-associated cells in >90% of our patients

• Bria-IMT™ increases the immune response, while checkpoint inhibitors decrease immune suppression

• Bria-IMT™ appears to have exerted additive or synergistic tumor-directed effects with checkpoint inhibitors

• BriaCell’s hypothesis: Checkpoint inhibitors act by "awakening" a component of the immune system, while Bria-

IMT™ "puts the foot on the gas" of the immune system, which may lead to more powerful anti-tumor activity

How Do Checkpoint Inhibitors Work?

• PD-L1 molecules block immune cells from attacking cancer cells

• Immune checkpoint inhibitors are designed to neutralize this immune suppression in cancer patients

BriaCell is currently dosing Bria-IMT™ with Incyte’s selected compounds under a corporate collaboration

Bria-IMT™ + Immune Checkpoint Inhibitor Combination Study Data

10

Phase I/IIa Combination Study in Advanced Breast Cancer

Patients were treated with the combination of Bria-IMT™ and anti-PD-1 antibody KEYTRUDA®.

An excellent safety and tolerability profile on the first 11 patients was observed.

All 11 patients were very heavily pre-treated with a median of 5 prior systemic therapy regimens (such as chemotherapy).

Most had very weak immune systems, further emphasizing the importance of the positive results observed.

As BriaCell had been purchasing the KEYTRUDA® for the study from Merck without a supply agreement, the study was switched to evaluating combination therapy with Incyte drugs and the combination with KEYTRUDA® was discontinued.

Patient HLA Match Observations Notes

1 0

25% reduction in sum of diameters of target liver metastases (breast cancer tumors in the liver).

8 prior chemotherapy or biological therapy regimens with extensive tumor growth in her liver.

Not an HLA match with Bria-IMT™ suggesting that—in combination with KEYTRUDA®—tumor reduction may occur without a match.

5 2

70% reduction in sum of diameters of target adrenal metastasis and complete resolution of orbital (behind the eye) metastasis.

Failed 12 prior regimens with 16 agents (13 chemotherapy and 3 hormonal).

Match at HLA-C and HLA-DRB3 loci.

Rolled-over from Bria-IMT™ study

Remarkable Responder announced Sept. 2019

Did not roll over

Bria-IMT™ + Immune Checkpoint Inhibitor: Remarkable Responder

11

Complete resolution of orbital tumor in a heavily pre-treated patient with 2 HLA matches and a grade II tumor supports remarkable activity of the Bria-IMT™ combination regimen, and it is

worth noting that checkpoint inhibitors have not proven effective as monotherapy in advanced breast cancer

Tumor behind the left eye causing proptosis completely resolves

Baseline Scans

Six months On Treatment Scans

Summary: Bria-IMT™ in Advanced Breast Cancer Trials

12Sources: 1- Wiseman CL, Kharazi A. The Open Breast Cancer Journal, 2010, 2, 4-11; 2- Lacher et al. Front. Immunol. 9:776; 3- Williams et al. San Antonio Breast Cancer Symposium (SABCS), December 2019

Proof-of-concept trial Phase I/IIa monotherapy Phase I/IIa combination w/Keytruda®1 2

Median survival was in line or above

expected survival for salvage therapies (6-

12 months)

One patient with 2 HLA matches to Bria-

IMT™ developed prompt objective

complete remission of a lung lesion on CT

scans and near-complete regression of

multiple breast lesions on MRI

All 3 patients with grade I/II tumors had

disease control (100%)

Patients with grade I or II tumors and those

able to generate a robust immune

response appear more likely to respond

regardless of HLA match, suggesting PD1

inhibitor can compensate for lack of HLA

match

Bria-IMT™’s data in monotherapy showed

significant disease control in patients with

increasing number of HLA matches

PD-L1 expression was seen on Cancer-

Associated Macrophage-Like Cells (CAMLs)

in 21/23 patients

PatientsHLA

match

*Disease

Control

**Disease Control in immune

responders

N=6 ≥2 50% 75%

N=20 ≥1 25% 33%

N=7 0 29% 29%

*Includes 1 PR and 7 SD

**Immune response measured by delayed-type hypersensitivity.

Note that this includes the 4 patients from the second trial

PatientsHLA

match

*Disease

Control

**Disease Control in immune

responders

N=5 ≥2 40% 100%

N=7 ≥1 43% 75%

N=4 0 25% 25%

*Includes 1 PR and 3 SD

**Immune response measured by delayed-type hypersensitivity.

Note that this includes the 4 patients from the monotherapy trial

3

Bria-IMT™ shows significant disease control in immune responders with increasing numbers of HLA matches both in monotherapy and in combination with Keytruda®

POC trial (2004-2006)

Patients N=4 (stage IV)

Safety ProfileWell tolerated; no

severe AEs

Median Survival 35 months

13

Summary: Bria-IMT™ in Advanced Breast Cancer Trials

Phase I/IIa monotherapy1&2

Patient characteristics

No HLA

matches

(n=7)

≥1 HLA

matches

(n=20)

≥2 HLA

matches (n=6)

Age 54 ± 15 60 ± 10 60 ± 15

Median Prior Systemic Regimens

7 (range 2-9) 4 (range 0-12) 5 (range 1-10)

% ER/PR + 67% 47% 80%

% Her2/neu + 14% 16% 0%

% Triple Negative 33% 37% 20%

Disease Control 2/7 (29%) 6/20 (30%) 4/6 (67%)

DTH Response 7/7 (100%) 14/20 (70%) 4/6 (67%)

Disease Control in DTH Responders

2/7 (29%) 6/14 (43%) 4/4 (100%)

% Grade I or II 2/7 (29%) 6/20 (30%) 3/6 (50%)

Disease Control in Grade I or II

2/2 (100%) 3/6 (50%) 3/3 (100%)

No HLA

matches

(n=4)

≥1 HLA

matches (n=7)

≥2 HLA

matches (n=5)

Age 61 ± 11 61 ± 9 60 ± 11

Median Prior Systemic Regimens

6 (range 2-10) 4 (range 1-14) 4 (range 1-14)

% ER/PR + 75% 67% 50%

% Her2/neu + 50% 50% 50%

% Triple Negative 0% 0% 0%

Disease Control 1/4 (25%) 3/8 (38%) 2/6 (33%)

DTH Response 4/4 (100%) 4/6 (67%) 2/4 (50%)

Disease Control in DTH Responders

1/4 (25%) 1/4 (25%) 1/2 (50%)

% Grade I or II 1/3 (33%) 2/6 (33%) 1/4 (25%)

Disease Control in Grade I or II

1/1 (100%) 2/2 (100%) 1/1 (100%)

Phase I/IIa combination with Keytruda®3

Patient characteristics

Sources: 1 - Lacher et al. Front. Immunol. 9:776; 2 - Williams et al. San Antonio Breast Cancer Symposium (SABCS), December 2019

Importantly, the latest trials have included patients with a diversity of HR/Her2 status who have failed multiple prior systemic regimens

Bria-IMT™ in Grade I/II Tumors

14

We believe these findings identify a patient population with higher clinical benefit rates

Breast Cancer Grade Correlates with Response Bria-IMT™ is derived from a grade II (moderately differentiated) breast cancer.

Genes expressed by Bria-IMT™ match best with grade I/II-derived Breast Cancer Cell Lines

~40% of recurrent breast cancers are grade I/II

Cell Lines

B00

1

06-0

04

05-0

02

04-0

03

03-0

01

06-0

01

01-0

02

06-0

05

A00

2

-100

-75

-50

-25

0

25

50

75

100

All Lesions %Changes

Patient

%C

ha

ng

e in

Gre

ate

st

Dia

mete

rs

Monotherapy

Combination Therapy

Monotherapy StudyGrade I/II patients with immune responses had clinical benefit (5/7 = 71%)

Patients very heavily pre-treated, median of 7 prior regimens

Combination StudyGrade I/II patients with immune responses had clinical benefit (3/3 = 100%)

Patients very heavily pre-treated with 14-15 prior regimens

5 / 7

3 / 3

Grade I/II Patients% Change Lesions

Median Overall Survival of 12.5 months

Recent publication in 3rd line patients (Kazmi S et al Breast Cancer Res Treat. 2020 Aug 17) showed a median overall survival of 7.2 - 9.8 months

Introducing… Bria-OTS™

15

Bria-OTS™: Off-The-Shelf Personalized ImmunotherapyConfirmation of “Matching Hypothesis” resulted in BriaCell’s “OTS” strategy

• Cooperative Research and Development Agreement with the National Cancer Institute, part of the National Institutes of Health

• We believe our treatment is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type

• We are engineering 15 unique HLA types (molecules), collectively referred to as Bria-OTS™, allowing for what we believe will be matching and treatment of over 99% of patients with advanced breast cancer

• Bria-OTS™ involves a simple saliva test to determine the HLA-type of each patient• Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation

• Similar cell lines in development for prostate cancer, lung cancer, and melanoma, as well as a pre-clinical Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (USA)

We anticipate each patient will be treated with a pre-manufactured formulation based on HLA-type

Saliva TestCell-Types Identified

Bria-OTS™ Formulation Determined

Patient Treatment

Timeline for Key Clinical Programs in Breast Cancer

16

Clinical data to be submitted to key scientific meetings including AACR, ASCO, and the San Antonio Breast Cancer Meeting

Anticipated Milestones

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

Bria-IMT™ + Incyte Compounds – Pre‐Registration Study Data

Bria-OTS™ – Authorization by FDA; 1st Patient Dosed

Bria-OTS™ – Pre‐Registration Study Data

Registration Study – Bria-IMT™ + Checkpoint Inhibitor

Registration Study – Bria-OTS™ + Checkpoint Inhibitor

2021 2022 2023

BriaCell Therapeutics Corp.

info@BriaCell.com BriaCell.com 1-888-485-6340

17

Thank you